Benzinga | Jul 7, 2021 11:27AM EDT

BioCopy, Immatics Team Up For Characterization Of TCR-Peptide-HLA Interactions

* Switzerland-based BioCopy AG has collaborated with Immatics N.V. (NASDAQ:IMTX) to characterize T cell receptors (TCRs).

* T cell receptors and their interactions with peptide-HLA complexes (human leukocyte antigen) play a crucial role for the human immune system in recognition of tumors, among other things.

* BioCopy's technology enables high-throughput screening of T cell receptors for binding to a wide variety of peptide-HLA complexes, thus contributing a safety screening for novel TCR-based cancer cell therapies.

* This collaboration aims to enable the characterization of more than 5,000 different TCR-peptide-HLA interactions simultaneously to accelerate the development of T-cell-based cancer therapies by facilitating large pre-clinical safety screenings.

* Price Action: IMTX shares are down 0.34% at $11.75 on the last check Wednesday.